Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “mHSPC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT06072196
What this trial is testing

Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Who this might be right for
Prostatic Neoplasms
Pfizer 3,017
Testing effectiveness (Phase 2)WithdrawnNCT06392841
What this trial is testing

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Deleterious HRR Gene MutationBRCA1 Gene Mutation+7 more
Qian Qin
Testing effectiveness (Phase 2)Looking for participantsNCT07650240
What this trial is testing

Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

Who this might be right for
Recurrent Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8Castration-Sensitive Prostate Cancer+9 more
Mayo Clinic 202
Not applicableLooking for participantsNCT07406282
What this trial is testing

Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Who this might be right for
Prostatic NeoplasmsMetastatic Hormone-Sensitive Prostate Cancer
Bayer 1,400
Large-scale testing (Phase 3)Study completedNCT04191096
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 1,251
Large-scale testing (Phase 3)Active Not RecruitingNCT02489318
What this trial is testing

Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

Who this might be right for
Prostate Cancer
Aragon Pharmaceuticals, Inc. 1,052
Not applicableLooking for participantsNCT07181122
What this trial is testing

Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Ankara Etlik City Hospital 102
Large-scale testing (Phase 3)Looking for participantsNCT03903835
What this trial is testing

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Karolinska Institutet 750
Large-scale testing (Phase 3)Looking for participantsNCT07751133
What this trial is testing

Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

Who this might be right for
Prostate CancermHSPCmCRPC
University College, London 1,500
Early research (Phase 1)Active Not RecruitingNCT05983198
What this trial is testing

Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 33
Not applicableStudy completedNCT06498921
What this trial is testing

An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 106
Testing effectiveness (Phase 2)Looking for participantsNCT07503379
What this trial is testing

Evaluation of the Efficacy and Safety of Darolutamide + ADT Combined With Low-dose Docetaxel in mHSPC

Who this might be right for
mHSPC
Yonghong Li 109
Not applicableStudy completedNCT05901649
What this trial is testing

The Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Janssen-Cilag Ltd. 505
Large-scale testing (Phase 3)Looking for participantsNCT05983783
What this trial is testing

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Who this might be right for
Metastatic Prostate CancerHormone Sensitive Prostate CancerChemotherapy Effect
The First Affiliated Hospital with Nanjing Medical University 200
Large-scale testing (Phase 3)Active Not RecruitingNCT04720157
What this trial is testing

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Prostatic Neoplasms
Novartis Pharmaceuticals 1,140
Not applicableStudy completedNCT07086651
What this trial is testing

Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Cancer of the ProstateProstate Neoplasms+1 more
Pfizer 1,300
Large-scale testing (Phase 3)Study completedNCT02677896
What this trial is testing

Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 1,150
Not applicableLooking for participantsNCT05649943
What this trial is testing

Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 566
Testing effectiveness (Phase 2)Looking for participantsNCT07216248
What this trial is testing

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
University of Utah 160
Large-scale testing (Phase 3)Looking for participantsNCT06350825
What this trial is testing

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Who this might be right for
Metastatic Prostate CancerTherapy, Directly Observed
The First Affiliated Hospital with Nanjing Medical University 200
Next Page